Antegren Brand Rejected Due To Possible Confusion With Ativan, Integrilin
This article was originally published in The Pink Sheet Daily
Elan and Biogen Idec agreed to change the name of the multiple sclerosis monoclonal antibody natalizumab from Antegren to Tysabri after FDA expressed concern over potential drug name mix-ups
You may also be interested in...
Elan/Biogen Idec may price the recently approved Tysabri at a premium to other multiple sclerosis therapies in anticipation of the additional indications. The price announcement could come within a few days.
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.